Who We Are

Zymeworks is a global biotechnology company developing novel, multifunctional therapeutics to address difficult-to-treat cancers and other serious diseases.

We are driven by our mission to make a meaningful difference for people around the world who are impacted by difficult-to-treat cancers and other serious diseases. Our complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics.

Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need.

In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies.

Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers.

Leadership Team

Kenneth Galbraith

Chair & CEO

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Liminal BioSciences Inc., Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

 

Paul Moore

PhD

Chief Scientific Officer

Paul Moore

PhD

Chief Scientific Officer

Dr. Moore joined Zymeworks in July 2022 and currently serves as our Chief Scientific Officer. Dr. Moore brings over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients with difficult-to-treat cancers and autoimmune conditions. Before joining Zymeworks, Paul served as Vice President, Cell Biology, and Immunology at MacroGenics, where he worked on the development of numerous clinical stage compounds and scientific collaborations with a range of pharmaceutical partners, including Pfizer, Servier, Gilead, Takeda, Janssen, Roche and Zai Labs. Prior to joining MacroGenics, he was Director of Cell Biology at Celera where he oversaw research efforts to develop novel antibody-based therapeutics. Dr. Moore began his career at Human Genome Sciences (HGS), holding several titles within research culminating in Director of Lead Product Development, where he managed various genomic-based target discovery programs including efforts that led to the discovery, development, approval, and commercialization of Benlysta (belimumab) for the treatment of systemic lupus erythematosus. Dr. Moore received a PhD in molecular genetics from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology in Nutley, New Jersey, and also holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 75 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.

Chris Astle

PhD

Senior Vice President & Chief Financial Officer

Chris Astle

PhD

Senior Vice President & Chief Financial Officer

Dr. Astle joined Zymeworks in April 2021 and currently serves as Senior Vice President and Chief Financial Officer. Prior to joining Zymeworks, Dr. Astle worked as a Chief Financial Officer at the CFO Centre in British Columbia, Canada from March 2020 to March 2021, and as Vice President, Finance at Alder BioPharmaceuticals Inc. in Seattle, Washington from April 2019 to February 2020. From August 2017 to January 2020, he served as Chief Executive Officer and founder of Think Forwards, a boutique financial consulting firm in London, UK. Dr. Astle worked at Allergan from 2011 to 2017, including as the Associate Vice President Finance, International Division from July 2016 to July 2017, managing multiple product launches, M&A transactions and restructurings, with a team of 170 across 60 countries. He is a UK Chartered Accountant (ICAS), qualifying at PwC London, UK in Audit & Pharmaceutical Performance Improvement Consulting with audit clients including GSK. Dr. Astle serves as a member of the board of directors at Healome Therapeutics, a private biotechnology company (2021-present).  During his time in the UK, he was the Chair of the 2018 CFO Agenda conference, guest lecturer at the Henley Business School, and judge at the British Accountancy Awards. Dr. Astle holds a PhD in Organic Chemistry from the University of Bristol (UK) and a MChem in Chemistry from the University of Liverpool (UK) and is also a certified ski instructor.

Jeffrey Smith

MD, FRCP

Executive Vice President and Chief Medical Officer

Jeffrey Smith

MD, FRCP

Executive Vice President and Chief Medical Officer

Dr. Smith joined Zymeworks in January 2023 and currently serves as our Executive Vice President and Chief Medical Officer based at our European hub in Dublin, Ireland. Dr. Smith has held many senior positions within the pharmaceutical industry, most recently, Managing Director of Alder Biopharmaceuticals Inc. Dublin, Ireland and before that Senior Vice President, Translational Medicine at Alder Biopharmaceuticals Inc, Seattle. Dr. Smith was responsible for the clinical development (phase I – III) of eptinezumab (anti-CGRP antibody for migraine) and clazakizumab (anti -IL-6 antibody for rheumatoid arthritis and cancer cachexia). Dr. Smith was also a founder of Alder Biopharmaceutcials Inc (founded 2004). Dr. Smith received his MB BS and MD from the University of London, UK and is a Fellow of the Royal College of Physicians in London.

Daniel Dex

JD

Senior Vice President, Corporate Secretary and General Counsel

Daniel Dex

JD

Senior Vice President, Corporate Secretary and General Counsel

Mr. Dex joined Zymeworks in September 2017, and currently serves as our Senior Vice President, Corporate Secretary and General Counsel. Mr. Dex brings over 25 years of diverse legal experience to Zymeworks, having worked in private practice at prominent law firms in both the U.S. and Canada, in-house with Avigilon Corporation (a Motorola Solutions company) and the New York Public Library, and with the U.S. federal district court for the Eastern District of Pennsylvania. Mr. Dex received a J.D. from the University of Pennsylvania Law School and a B.A. from Brown University. He is a member of the bars of both New York and British Columbia.

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mark Hollywood

Executive Vice President and Head of Technical and Manufacturing Operations

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Head of Technical and Manufacturing Operations. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

John Fann

PhD

Senior Vice President, Process Sciences

John Fann

PhD

Senior Vice President, Process Sciences

Dr. Fann joins Zymeworks with more than 20 years of experience in bioprocess development and biologics manufacturing and controls. Dr. Fann started his postdoctoral career with StemCell Technologies in Vancouver, then joined Seattle Genetics in its early years. After establishing the upstream function and accomplishing the first technology transfer and clinical manufacturing for Seagen, Dr. Fann joined AbbVie Bioresearch Center. He held several leadership positions in Process Sciences and MS&T. At AbbVie, Dr. Fann experienced many clinical projects and helped to launch and scale up several commercial biotherapeutics, including the blockbuster drug Humira. Dr. Fann joined Bristol Myers Squib after returning to Seattle, as the head of M&ST and Bioprocess Development. He was leading microbial process development at BMS and accomplished several early and late-stage clinical projects. Prior to Zymeworks, Dr. Fann was VP of Bioprocess R&D at AGC Biologics, leading the global new technology development at AGC. Dr. Fann holds a Ph.D. in Chemical Engineering from the University of British Columbia.

Raquera Brown

Vice President, Quality

Raquera Brown

Vice President, Quality

Ms. Brown joined Zymeworks in September 2022 and serves as our Vice President, Quality. Ms. Brown brings over 25 years of experience in the pharmaceutical and biotechnology industries. Prior to joining Zymeworks, Ms. Brown served as Senior Director/Head of Quality Sio Gene Therapies. She has held roles of increasing leadership responsibility in Research and Development, Quality Control, GMP Quality, Compliance, Clinical and Nonclinical QA working across multiple dosage forms, therapeutic areas, and lifecycle phases at organizations including Merck, Novartis, Schering-Plough, and Endo Pharmaceuticals.  Ms. Brown received a Bachelor of Science degree in Biological Sciences from Rutgers University.

Bijal Desai

MBA

Vice President, Finance & Strategy

Bijal Desai

MBA

Vice President, Finance & Strategy

Ms. Desai joined Zymeworks in May 2020 and currently serves as the Vice President, Finance & Strategy. Ms. Desai brings more than 17 years of experience providing oversight of operational and strategic finance support in the customer service, technology, and life sciences industries. Prior to joining Zymeworks, Ms. Desai held a variety of R&D and Commercial FP&A and Corporate Strategy positions, starting with CTI BioPharma, Juno Therapeutics, and Alder BioPharmaceutical Inc. Ms. Desai holds her MBA with a concentration in Finance from Texas A&M University, and is an active member of Healthcare Businesswomen’s Association (HBA) Seattle Chapter holding the position of Mentoring Chair.

Lucas Donigian

MBA

Vice President, Business & Commercial Development

Lucas Donigian

MBA

Vice President, Business & Commercial Development

Mr. Donigian joined the Business Development group at Zymeworks in March 2020 and has been serving as Vice President, Business & Commercial Development since January 2024. Mr. Donigian has over 15 years in the biotechnology and biopharma industry across drug development and diagnostics. Prior to joining Zymeworks, Mr. Donigian was the Director of Business Development and BioPharma collaborations at NanoString Technologies, where he lead diagnostics business development efforts. Prior to that, Mr. Donigian was a Corporate Development consultant with Dendreon where he facilitated buy and sell side M&A analysis for late-stage opportunities. Mr. Donigian started his career developing novel cancer stem cell therapeutics at OncoMed Pharmaceuticals helping to bring multiple therapeutic candidates into first in human trials. Mr. Donigian received his Molecular Biology and Organic Chemistry from San Jose State University and an MBA from the University of Washington.

Lindsey Foulkes

PhD, BSc

Vice President, Corporate Development

Lindsey Foulkes

PhD, BSc

Vice President, Corporate Development

Dr. Foulkes joined Zymeworks in January 2024, bringing over 25 years of experience in the biotechnology, biopharma and medical device industries. Prior to joining Zymeworks, Dr. Foulkes was Chief Operating Officer of Arecor, a UK AIM-listed, clinical-stage biopharmaceutical company. Joining at the point of IPO, she implemented organizational and operational changes to position the company for future growth. Dr. Foulkes has held senior commercial roles covering corporate and business development, marketing and clinical portfolio management, with a therapeutic focus on immunology, inflammation, oncology and rare diseases. She has worked for organizations including Liminal Biosciences (previously known as Prometic Life Sciences), Acambis, and Cangene Corporation, and she was part of the start-up team for the medical device company, Nexan Ltd. Dr. Foulkes started her commercial career in management consultancy with McKinsey & Company and during her career she has also worked as a freelance consultant providing business development, strategy and market analysis support within the biotechnology industry, with a focus on oncology and immunology companies. Dr. Foulkes holds a PhD in Leukaemia Research and a BSc in Immunology, awarded by the University of Glasgow.

Cathie Graham

JD

Vice President, Legal

Cathie Graham

JD

Vice President, Legal

Ms. Graham joined Zymeworks in September 2018, and currently serves as our Vice President, Legal. Ms. Graham brings over 17 years of diverse legal experience to Zymeworks, having previously worked in private practice for over a decade at one of Canada’s largest law firms, and in-house with Avigilon Corporation (a Motorola Solutions company). Ms. Graham received a LL.B/J.D. from Queen’s University and a Bachelor of Arts from Concordia University. She is a member of the bar in British Columbia.

Laura O’Connor

Vice President, Human Resources & DEI

Laura O’Connor

Vice President, Human Resources & DEI

Ms. O’Connor joined Zymeworks in 2020 and currently serves as our Vice President, Human Resources & DEI. Ms. O’Connor brings more than 20 years of experience within Human Resources, specializing in the pharmaceutical and biotech industry for over 13 years. Prior to joining Zymeworks, Ms. O’Connor held a variety of Human Resources leadership positions, starting with PointClickCare, Takeda Canada, Ferring Pharmaceuticals and most recently Merz Pharma. Ms. O’Connor holds a Bachelor of Arts degree in Psychology from the University of Waterloo and a certificate in Strategic Human Resources Management from the Rotman School of Business.

Barbara Schaeffler

MBA

Vice President, Clinical Development Operations

Barbara Schaeffler

MBA

Vice President, Clinical Development Operations

Ms. Schaeffler joined Zymeworks in January 2024, bringing over 27 years of experience in the biotechnology and biopharma industries. Prior to joining Zymeworks, Ms. Schaeffler was Vice President of Clinical Operations at Syndax Pharmaceuticals, a clinical-stage oncology company developing first-in-class therapies for acute leukemias and chronic graft-versus host disease. Ms. Schaeffler has held senior roles covering clinical development and operations, leading departments and project development teams through all phases of clinical trials, culminating in regulatory filings and drug approvals. She has worked for organisations including Lundbeck, Alder Biopharmaceuticals (acquired by Lundeck), Poniard Pharmaceuticals (formerly NeoRx, Corporation), Pathogenesis and Chiron (acquired by Novartis) and PATH. Ms. Schaeffler holds an MBA and a bachelor’s degree in Bacteriology from the University of California.

Joe Woolery

PharmD, BCOP

Vice President, Early-Stage Development (Americas)

Joe Woolery

PharmD, BCOP

Vice President, Early-Stage Development (Americas)

Dr. Woolery joined Zymeworks in September 2019 and currently serves as our Vice President, Early-Stage Development in the Americas and Global Lead for zanidatamab zovodotin (ZW49). Dr. Woolery previously held positions at Seagen working on registrational studies with Adcetris in Peripheral T-Cell Lymphoma and Tukysa in HER2+ Metastatic Breast Cancer. Prior to transitioning to the pharmaceutical industry, Dr. Woolery practiced as a Clinical Oncology Pharmacist at the University of Texas M.D. Anderson and Banner M.D. Anderson Cancer Centers. Dr. Woolery received a PharmD from the University of Missouri-Kansas City. He also completed residency’s in clinical pharmacy practice at The University of Arizona and oncology fellowship at H. Lee Moffitt Cancer Center and Research Institute. Dr. Woolery is a board certified oncology pharmacist and a member of the American Society of Clinical Oncology and the European Society of Medical Oncology.

Josemund Menezes

MBBS, BCMAS

Managing Director, Early-Stage Development (Asia Pacific)

Josemund Menezes

MBBS, BCMAS

Managing Director, Early-Stage Development (Asia Pacific)

Dr. Menezes has over 18 years of industry experience across MNC Pharma, biotech and CRO, spearheading global clinical development (Phase I to III executional strategy) in Oncology, Vaccines, and Immunology therapy areas. Prior to joining Zymeworks, Dr. Menezes held cross-functional team management and leadership roles at ASLAN Pharmaceuticals, Tessa Therapeutics, and Sanofi Pasteur. Dr. Menezes graduated from Maharashtra University of Health Sciences, India with a Bachelor of Medicine and Bachelor of Surgery (MBBS) degree, followed by advanced certifications in Clinical Research, Vaccinology, Project Management and Board Certified Medical Affairs Specialist (BCMAS) training from ACMA, USA.

Board of Directors

Kenneth Galbraith

Chair & CEO

Kenneth Galbraith

Chair & CEO

Mr. Galbraith has served as Zymeworks’ Chair & CEO since January 2022. Mr. Galbraith has over 35 years’ experience in biotechnology and venture capital having acted as an executive, director, investor as well as an advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors across North America and the UK in the growth of both private and public companies from an early-stage through regulatory approval and commercialization. Ken has worked with many biotechnology companies including: Liminal BioSciences Inc., Macrogenics, AnorMED, Alder Pharmaceuticals, Celator Pharmaceuticals, Novadaq, Profound Medical, Fairhaven Pharmaceuticals, Tekmira, Angiotech, Aquinox, and Xenon Pharmaceuticals among others. Mr. Galbraith currently serves on the board of directors of Profound Medical He earned a Bachelor of Commerce (Honors) degree from the University of British Columbia in 1985.

 

Carlos Campoy

MBA

Director

Carlos Campoy

MBA

Director

Mr. Campoy has served as a member of our Board of Directors since June 2023. Mr. Campoy began his life sciences industry career at Eli Lilly and Company in 1996, serving in a variety of senior financial leadership roles in the U.S., Japan, Latin America and Europe over an 18-year span. As the Chief Financial Officer at Alder Biopharmaceuticals in Seattle, Washington, he led successful capital markets transactions to fund commercialization readiness for eptinezumab and played a key role in the eventual acquisition of Alder Biopharmaceuticals by Lundbeck in 2019 in a cash transaction in excess of $2 billion. Preceding his role at Alder Biopharmaceuticals, Mr. Campoy was a partner at Think Forwards, a boutique financial consulting firm. He previously held financial leadership positions at Allergan plc and, most recently, was the Chief Financial Officer at CytomX Therapeutics. Throughout his time in these financial roles, Mr. Campoy attained a Certified Management Accountant (CMA) designation. He received an MBA in Finance and Decision Information Systems from Indiana University and a Bachelor of Science degree in Management from Faculdade C.C. Administracao de Tupa (FACCAT) in Brazil.

Alessandra Cesano

MD, PhD

Director

Alessandra Cesano

MD, PhD

Director

Dr. Cesano has served as a member of our Board of Directors since February, 2024. Dr. Cesano currently serves as a director at Puma Biotechnology and Summit Therapeutics. Since July 2019, she has served as the Chief Medical Officer of ESSA Pharmaceuticals, a pharmaceutical company developing therapies for the treatment of prostate cancer. Prior to joining ESSA, Dr. Cesano was the Chief Medical Officer of NanoString Technologies, Inc. from July 2015 to July 2019, where she focused on the development of translational and diagnostic multi-plexed assays for the characterization and measurement of mechanisms of immune response and resistance. Dr. Cesano has also held management positions at Amgen Inc., Biogen Inc. (formerly Biogen Idec) and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late-stage development and FDA approval. She currently serves as associate editor for the Biomarker section of the Journal for ImmunoTherapy of Cancer and co-chair of the Society for Immunotherapy of Cancer regulatory committee. She has been an author on more than 140 publications. Dr. Cesano received an MD summa cum laude, a board certification in oncology and a PhD in tumor immunology from the University of Turin, Italy.

Troy Cox

MBA

Director

Troy Cox

MBA

Director

Mr. Cox has served as a member of our Board of Directors since June 2019. Mr. Cox served as Chief Executive Officer of Foundation Medicine, Inc. from February 2017 through February 2019, as a member of Foundation Medicine’s board of directors from February 2017 until July 2018, and in the additional role of President of Foundation Medicine from February 2018 until July 2018. Prior to Foundation Medicine, Mr. Cox served as Senior Vice President, Sales & Marketing at Genentech, Inc. from February 2010 until February 2017. Before joining Genentech, Mr. Cox served as President of CNS operations at UCB S.A., with responsibility for developing and commercializing therapeutics for diseases primarily related to the central nervous system. Prior to UCB BioPharma, Mr. Cox held senior commercial leadership roles with Sanofi-Aventis and Schering-Plough. Mr. Cox has been on the board of directors at SOPHiA GENETICS SA since July 2019. He has also served on the board of directors of SomaLogic, Inc. from September 2021 until January 2024, and as the Executive Chair of the board from October 2022 to March 2023. Mr. Cox has served on the board of directors of Standard BioTools Inc. from January 2024 to present. Mr. Cox received a BBA in finance from the University of Kentucky and an MBA from the University of Missouri.

Nancy Davidson

MD

Director

Nancy Davidson

MD

Director

Dr. Davidson has served as a member of our Board of Directors since December 2023. Dr. Davidson is a medical oncologist and researcher who is a top opinion leader in the field of breast cancer biology and treatment, with a particular interest in developing evidence-based clinical pathways in breast cancer treatment. She is currently the Executive Vice President for Clinical Affairs, Raisbeck Chair for Collaborative Research and Professor of Fred Hutchinson Cancer Center (“FHCC”). Dr. Davidson also serves as a Professor at the University of Washington Department of Medicine based in Seattle where she previously held the role of Head of the Division of Medical Oncology from December 2016 to August 2023. During this time, Dr. Davidson served as the President and Executive Director of the Seattle Cancer Care Alliance from December 2016 to April 2022. Prior to joining FHCC, she spent time at the National Cancer Institute, Johns Hopkins in Baltimore and the University of Pittsburgh. Dr. Davidson is a past-President of both the American Society of Oncology and the American Association for Cancer Research and has served on a variety of board of directors and advisory committees in the oncology field. She has authored more than 400 publications during her career and has received many awards, honors, and appointments. These include: The Brinker International Award for Breast Cancer Research, the Rosalind E. Franklin Award for Women in Science from the National Cancer Institute (2008), and election to the National Academy of Medicine (2011) and the American Academy of Arts and Sciences (2019). She has also been listed among Thomson Reuters Highly Cited Researchers (2014-2015). After receiving a BA in Molecular Biology from Wellesley College, she went on to obtain an MD from Harvard Medical School. Dr. Davidson completed her residency in Internal Medicine at John Hopkins Hospital and a fellowship at the National Cancer Institute.

Sue Mahony

PhD MBA

Lead Independent Director

Sue Mahony

PhD MBA

Lead Independent Director

Dr. Mahony has served as a member of our Board of Directors since June 2019 and as the Lead Independent Director since December 2023. Dr. Mahony is an executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served as Senior Vice President of Eli Lilly and Company and President of Lilly Oncology from February 2011 until August 2018. She joined Lilly in 2000, holding senior leadership positions in product development, marketing, human resources, and general management. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen, and Bristol-Myers Squibb. Dr. Mahony has served on the board of directors of Assembly Biosciences, Inc. since December 2017 and on the board of directors of Axsome Therapeutics, Inc. since October 2023. She previously served on the board of directors of Vifor Pharma from May 2019 until August 2022, and served on the board of directors of Horizon Therapeutics Public Limited Company from August 2019 to October 2023 (acquired by Amgen Inc.). Dr. Mahony received a BSc and a PhD from Aston University and an MBA from London Business School.

Derek Miller

MBA

Director

Derek Miller

MBA

Director

Mr. Miller has been a member of our Board of Directors since April 2023. Mr. Miller has been a leader in the biotechnology and pharmaceutical sector for more than 25 years with experience in corporate development, business development and global commercial strategy. He is an independent commercial and business development consultant for a clinical-stage oncology company and a late-stage ultra-rare disease company, and currently serves as Chief Executive Officer of a cell and gene therapy imaging startup venture, spun out from the University of Pennsylvania. Previously, he served as Chief Business Officer of Aro Biotherapeutics, a spinout of Janssen Pharmaceuticals, leading numerous strategic and operational initiatives including a transformative collaboration with Ionis with potential revenues for up to $1.4 billion. Mr. Miller also served as Chief Business Officer of Celator Pharmaceuticals where he led the development of their pipeline and business development strategy, resulting in its acquisition by Jazz Pharmaceuticals in 2016 for cash proceeds of approximately $1.5 billion. Prior to Celator Pharmaceuticals, Mr. Miller held a variety of marketing, sales and market access roles with Genentech, Centocor and GSK. Mr. Miller is a member of the Board of Trustees for the Eastern Pennsylvania Chapter of the Leukemia and Lymphoma Society and serves as a mentor for the Villanova School of Business. He received an MBA from Villanova University and Bachelor of Arts and Science degree from the University of Delaware.

Kelvin Neu

MD

Director

Kelvin Neu

MD

Director

Dr. Neu has served as a member of our Board of Directors since March 2020. Dr. Neu was a Partner at Baker Bros. Advisors LP, a registered investment adviser, from April 2004 until January 2021. Dr. Neu is Founder and Chief of Herringbone, a life sciences innovation practice established in January 2022. Dr. Neu is also Co-Founder and Chair of QDX Technologies Pte. Ltd., a computational chemistry company established in February 2023. Dr. Neu previously served on the board of directors of IGM Biosciences, Prelude Therapeutics, Idera Pharmaceuticals, Aquinox Pharmaceuticals and XOMA Corporation. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology PhD program at Stanford University as a Howard Hughes Medical Institute Fellow. Dr. Neu holds an AB (summa cum laude) from Princeton University, where he was awarded the Khoury Prize for graduating first in his department of Molecular Biology. Prior to attending Princeton, Dr. Neu served for two and a half years in the military of his native Singapore.

Scott Platshon

BSc

Director

Scott Platshon

BSc

Director

Mr. Platshon has served as a member of our Board of Directors since February, 2024. Mr. Platshon is a Partner at EcoR1 Capital and currently serves on the Board of Directors of Ajax Therapeutics, Kumquat Biosciences, and Terremoto Biosciences. Prior to joining EcoR1 in 2015, Mr. Platshon was an analyst at Aquilo Partners. He holds a Bachelor of Science in Bioengineering from Stanford University.

Hollings C Renton

MBA

Director

Hollings C Renton

MBA

Director

Mr. Renton has served as a member of our Board of Directors since February 2017. Mr. Renton served as Chief Executive Officer and President of Onyx Pharmaceuticals, Inc. from March 1993 to March 2008 and was the chair of the board of directors of Onyx from June 2000 to March 2008. Onyx was acquired by Amgen Inc. in 2013 for $10.4 billion. Before joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, from December 1991 to December 1993. Mr. Renton served in a variety of executive roles at Cetus Corporation from 1983, including as President from 1990 to 1991, Chief Operating Officer from 1987 to 1990 and Chief Financial Officer from 1983 to 1987, prior to its acquisition by Chiron in 1991. Mr. Renton has served on the board of directors of AnaptysBio, Inc. since June 2015. Previously, Mr. Renton served on the boards of four other biopharmaceutical companies: Portola Pharmaceuticals Inc., where he had also been board chair (March 2010 to July 2020), KYTHERA Biopharmaceuticals, Inc. (December 2014 to October 2015), Affymax, Inc. (June 2009 to November 2014) and Rigel Pharmaceuticals, Inc. (January 2004 to March 2014). Mr. Renton also served on the board of Cepheid Inc., a molecular diagnostics company, from March 2000 to November 2016. Mr. Renton received his MBA from the University of Michigan and his BS in Mathematics from Colorado State University.